Compare · INZY vs LLY
INZY vs LLY
Side-by-side comparison of Inozyme Pharma Inc. (INZY) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INZY and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.33T.
- LLY has hit the wire 44 times in the past 4 weeks while INZY has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 8 for INZY).
- Company
- Inozyme Pharma Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- -
- $1.33T
- 1M return
- -
- +14.11%
- 1Y return
- -
- +37.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 44
- Recent ratings
- 8
- 25
Inozyme Pharma Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest INZY
- Amendment: SEC Form SCHEDULE 13G/A filed by Inozyme Pharma Inc.
- SEC Form 15-12G filed by Inozyme Pharma Inc.
- SVP, CFO & Head of BD Subramanian Sanjay closing all direct ownership in the company (SEC Form 4)
- COO Winton Matthew closing all direct ownership in the company (SEC Form 4)
- Director Bolte Axel closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Sullivan Lynne Marie
- CEO & Chairman Treco Douglas A closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hopfner Robert Lorne
- SEC Form EFFECT filed by Inozyme Pharma Inc.
- SEC Form EFFECT filed by Inozyme Pharma Inc.
Latest LLY
- Director Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)
- Director Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)
- Director William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)
- Director Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)
- Director Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)
- Director Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)
- Director Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)
- Director Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)
- Director Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)
- Director J Erik Fyrwald was granted 175 shares, increasing direct ownership by 0.23% to 75,719 units (SEC Form 4)